292 related articles for article (PubMed ID: 17895832)
1. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Pham NA; Tsao MS; Cao P; Hedley DW
Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Yao J; Qian C
Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
[TBL] [Abstract][Full Text] [Related]
3. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Clin Cancer Res; 2001 Oct; 7(10):3269-75. PubMed ID: 11595724
[TBL] [Abstract][Full Text] [Related]
4. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Ng SSW ; Tsao MS; Chow S; Hedley DW
Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
7. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
8. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
9. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Meng Q; Shi S; Liang C; Liang D; Hua J; Zhang B; Xu J; Yu X
Oncogene; 2018 Nov; 37(44):5843-5857. PubMed ID: 29980787
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.
Yau CY; Wheeler JJ; Sutton KL; Hedley DW
Cancer Res; 2005 Feb; 65(4):1497-504. PubMed ID: 15735038
[TBL] [Abstract][Full Text] [Related]
12. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R
Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520
[TBL] [Abstract][Full Text] [Related]
14. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
16. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Verma A; Wang H; Manavathi B; Fok JY; Mann AP; Kumar R; Mehta K
Cancer Res; 2006 Nov; 66(21):10525-33. PubMed ID: 17079475
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
20. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]